EN DE

Dr Sulaiman Al Habib Medical Group (4013) Fair Value & Analysis

Healthcare · SA · Market cap 84.4B SAR (≈ $22.5B) · ISIN SA1510P1UMH1

What is Dr Sulaiman Al Habib Medical Group really worth?

DS Dr Sulaiman Al Habib Medical Group 4013 · SR
Price230.20 SAR
Fair Value112.37 SAR
Upside−51.2%
Quality55/100

A solid business, but trading 105% above our fair value of 112.37 SAR.

Watch Dr Sulaiman Al Habib Medical Group for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

Strengths

✓Solidly profitable · 16.6% net margin
✓Moderate debt · generates free cash flow
✓Wide moat 72/100

Risks

!Expensive Growth (revenue 5y +18.5 %/yr)
!Mixed vs. peers (7/14)
!The models disagree: range 49.04 SAR to 213.99 SAR

For context

·2.11% dividend yield
Evidence: High Range 49.04 SAR – 213.99 SAR

Fair value as of: Aug 30, 2026

From 22 valuation models · updated 6 days ago

Share price −3.6% over the past month.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

  • The price sits above even our optimistic bull case (213.99 SAR). The favourable scenario is already priced in.
  • The model range is unusually wide (49.04 SAR to 213.99 SAR). The outcome hinges heavily on assumptions, so read the point estimate with caution.
  • Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder.

Price vs Fair Value (5 years)

320.47 SAR 143.73 SAR Fair Value 112.37 SAR May 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 30, 2026.

How to read this chart

60‑month range 143.73 SAR – 320.47 SAR · fair‑value band 49.04 SAR – 213.99 SAR · the 230.20 SAR price screens above the 112.37 SAR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 30, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Dr Sulaiman Al Habib Medical Group (4013) currently trades at 230.20 SAR, while our model-based Fair Value estimate is 112.37 SAR, implying the stock looks roughly 104.9% overvalued today. The Quality Score stands at 55/100 (solid quality), in the Healthcare sector. Bull case: the Growth Earnings group reads highest at a median of 164.61 SAR per share, and 1 of the 22 models we run sit above the 230.20 SAR price. Bear case: the Asset-Based group reads lowest at 15.13 SAR, and 21 of the 22 models stay below the price. Evidence for this calculation is high.

Over the trailing twelve months, Dr Sulaiman Al Habib Medical Group generated revenue of 14.6B SAR at a net margin of 16.6%. Revenue grew 18.4% year over year. It earns a return on equity of 30.1%. Net debt stands at 7.0B SAR. Fundamentals as of Aug 30, 2026

Our scenario range runs from 49.04 SAR (bear case) to 213.99 SAR (bull case); at 230.20 SAR, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 17% below its 52-week high and 10% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −51%, 4013 screens richer than that median.

Fair Value models

This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly 1.26 SAR per share, which is 1.1 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
EPV best evidence 46.19 SAR 56.97 SAR 66.39 SAR 74
5Y EBITDA Exit 48.75 SAR 128.94 SAR 237.72 SAR 71
ROIC Compounder 58.10 SAR 92.09 SAR 136.50 SAR 70
All 22 models by family
DCF Models
5Y Revenue Exit 31.61 SAR 91.05 SAR 178.61 SAR 67
5Y EBITDA Exit 48.75 SAR 128.94 SAR 237.72 SAR 71
5Y P/E Exit 57.97 SAR 149.33 SAR 262.54 SAR 67
10Y Revenue Exit 14.45 SAR 66.75 SAR 160.33 SAR 59
10Y EBITDA Exit 28.72 SAR 95.67 SAR 213.36 SAR 62
10Y P/E Exit 35.02 SAR 111.24 SAR 235.63 SAR 58
Earnings-Based
Graham-Dodd 46.66 SAR 270.23 SAR 375.97 SAR 63
Lynch FV 76.32 SAR 109.03 SAR 141.73 SAR 61
PEG = 1.0 76.32 SAR 109.03 SAR 141.73 SAR 57
EPV best evidence 46.19 SAR 56.97 SAR 66.39 SAR 74
Dividend Discount
Gordon GGM 43.61 SAR 90.68 SAR 143.86 SAR 66
DDM Multi-Stage 43.61 SAR 76.47 SAR 95.17 SAR 66
Multiples
P/E Multiple 113.21 SAR 150.95 SAR 188.69 SAR 63
P/S Multiple 87.48 SAR 116.64 SAR 145.80 SAR 58
P/B Multiple 76.20 SAR 101.59 SAR 126.99 SAR 55
EV/EBIT 77.70 SAR 109.75 SAR 141.80 SAR 65
EV/EBITDA 80.89 SAR 113.99 SAR 147.10 SAR 67
EV/Revenue 50.18 SAR 79.59 SAR 109.00 SAR 53
Asset-Based
NCAV (Graham) 11.29 SAR 15.13 SAR 22.58 SAR 54
Economic Profit
Residual Income 42.40 SAR 51.43 SAR 200.91 SAR 64
ROIC Compounder 58.10 SAR 92.09 SAR 136.50 SAR 70
Growth Earnings
Growth-Adj P/E 115.23 SAR 164.61 SAR 213.99 SAR 67

Widest divergence: Growth Earnings (164.61 SAR) versus Asset-Based (15.13 SAR). Highest evidence: EPV (74).

Notify me when 4013 reaches fair value

Put 4013 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Free, no payment details. Unsubscribe anytime in one click.

Key figures & financial health

P/E ratio 33.3
P/S ratio 5.83 P/E × margin
EPS (TTM) 6.92 SAR price ÷ EPS = P/E 33.3
Dividend yield 2.1% payout 70.2%
Net margin 17.5% FY2025
Return on equity 30.1% TTM
More key figures
Profitability
Return on assets (EBIT) 12.6% avg 5y
Operating margin 19.2% TTM
Growth
Revenue (TTM) 14.6B SAR TTM
Revenue growth (YoY) +18.4% 3y avg +18.1%
EPS growth (YoY) +12.1%
Balance sheet & cash flow
Free cash flow 101M SAR FY2025
Net debt 7.0B SAR FY2025 · ≈ 69.3 yrs of FCF

Figures from reported company fundamentals · as of Aug 30, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 55/100

Of which business quality 53 · Market factors (momentum, volatility) 54

Profitability 62
Margins and returns on capital today
Quality Growth 50
Are margins and returns improving?
Cashflow 38
Earnings quality: real cash, not paper profit
Fin. Strength 64
Balance sheet, leverage, solvency risk
Investment 16
Disciplined investing over empire-building
Low Volatility 92
Calm price path (market factor)
Momentum 43
Price trend over the last 3–12 months (market factor)
52W Momentum 31
Distance to the 52-week high (market factor)
Net Issuance 82
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

Dr. Sulaiman Al Habib Medical Services Group Company, together with its subsidiaries, provides private health and support services in the Kingdom of Saudi Arabia. It operates through three segments: Hospitals/Healthcare Facilities, Pharmacies, and Other Solutions Sector.

Full company description

Dr. Sulaiman Al Habib Medical Services Group Company, together with its subsidiaries, provides private health and support services in the Kingdom of Saudi Arabia. It operates through three segments: Hospitals/Healthcare Facilities, Pharmacies, and Other Solutions Sector. The company establishes, manages, and operates hospitals, general and specialized medical complexes, day surgery centers, and pharmaceutical facilities. It also provides home medical care; specialized medical laboratories; information technology and systems; facility maintenance; telemedicine; revenue cycle management; and medical equipment maintenance services, as well as engages in real estate activities. The company was founded in 1993 and is based in Riyadh, the Kingdom of Saudi Arabia.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Dr Sulaiman Al Habib Medical Group reported revenue of 13.7B SAR in FY2025 versus 7.3B SAR in FY2021, a compound +17.3%/yr. Reported net income was 2.4B SAR in FY2025, compounding +14.9%/yr from FY2021.

Growth Quality 62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Latest Revenue (FY 2025)
13.7B SAR
Latest YoY
+22.4%
Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+18.1%
Avg. revenue growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+18.5%
Avg. revenue growth/yr (10Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+10.3%
Value creation/yr (5Y) ⓘEarnings growth per share (CAGR 5 years) plus dividend yield: value created per share and year.
+20.0% (17.9 + 2.1)
Revenue +17.3%/yr
FY21 7.3B SAR
FY22 8.3B SAR
FY23 9.5B SAR
FY24 11.2B SAR
FY25 13.7B SAR
Net income +14.9%/yr
FY21 1.4B SAR
FY22 1.7B SAR
FY23 2.0B SAR
FY24 2.3B SAR
FY25 2.4B SAR
Character of growth · EPS growth decomposed (2015-2025) +8.0 % p.a.
Revenue per share +10.3 %

of which total revenue +10.3 % · buybacks/dilution +0.0 %

EBIT margin −1.2 %
Tax rate +0.4 %
Residual (interest, one-offs) −1.3 %

Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).

4013 screens 105% overvalued. Compare with HCA Healthcare, Inc →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Dr Sulaiman Al Habib Medical Group · Fair Value
112.37 SAR −105%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Dr Sulaiman Al Habib Medical Group Fair Value". https://www.fairvalue-calculator.com/stock/4013

Peer Group

Medical Care Facilities · 257 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 55 · Above median
Fair Value upside −51% · Bottom 25%
Return on equity (TTM) 30% · Top 25%
Return on assets 7% · Top 25%
Net margin (TTM) 17% · Top 25%
Operating margin (TTM) 19% · Top 25%
Revenue growth 18% · Top 25%
Dividend yield (TTM) 2.1% · Below median
Debt / equity 1.11× · Higher than 75% of peers

Valuation Multiples vs Medical Care Facilities median · lower = cheaper

P/E (TTM) 33.3× · Pricier than median
P/B 2.84× · Pricier than median
P/S (TTM) 1.54× · Pricier than median
P/FCF 221.7× · Pricier than 75% of peers
EV/EBITDA 8.5× · Cheaper than median

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE0 · sector 23
FUTURE92 · sector 26
PAST100 · sector 30
HEALTH45 · sector 90
DIVIDEND42 · sector 43

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Aug 30, 2026).

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc HCA $417.82 $547.67 +31%
Fresenius SE FRE €45.25 €32.15 −29%
IHH Healthcare Berhad, an investment holding company, Q0F 2.67 SGD 1.44 SGD −46%
Tenet Healthcare Corporation THC $266.80 $330.25 +24%
DaVita Inc DVA $180.68 $186.49 +3%
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,818 ₹2,955 −66%
Fresenius Medical Care AG FME €39.92 €71.28 +79%
Aier Eye Hospital Group 300015 ¥8.25 ¥7.67 −7%
Max Healthcare Institute Limited MAXHEALTH ₹1,005 ₹284.87 −72%
Encompass Health Corporation EHC $120.31 $109.77 −9%

Compare Dr Sulaiman Al Habib Medical Group with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screener Filter by region, size and sector Compare tool Two stocks side by side Extrinsic Value Calculator (Options) Splits an option premium into intrinsic and extrinsic (time) value. Peter Lynch Fair Value Formula & Calculator Apply Peter Lynch's fair value formula in seconds: fair P/E ≈ earnings growth (+ dividend) - free, with formula and example.

Frequently asked questions

Is Dr Sulaiman Al Habib Medical Group (4013) overvalued or undervalued?
As of Aug 30, 2026, our model estimates a fair value of 112.37 SAR versus a price of 230.20 SAR, about −51% upside (overvalued).
What is the fair value of 4013?
Our model-based fair value for Dr Sulaiman Al Habib Medical Group is 112.37 SAR (as of Aug 30, 2026), built from audited fundamentals. The current price: 230.20 SAR.
What is the quality score of 4013?
Dr Sulaiman Al Habib Medical Group has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Dr Sulaiman Al Habib Medical Group (4013)?
Dr Sulaiman Al Habib Medical Group reported trailing-twelve-month revenue of about 14.6B SAR (latest available figure, as of Aug 30, 2026).
What is the net profit margin of 4013?
The net profit margin of Dr Sulaiman Al Habib Medical Group is about 16.6%, meaning it keeps roughly 16.6% of revenue as net income. Based on the latest reported figures.
Does Dr Sulaiman Al Habib Medical Group pay a dividend?
Dr Sulaiman Al Habib Medical Group currently shows a dividend yield of about 2.11% relative to its recent price (as of Aug 30, 2026).
Free · no account needed

Watch Dr Sulaiman Al Habib Medical Group in the live analysis

One click puts Dr Sulaiman Al Habib Medical Group on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.